Filing Details
- Accession Number:
- 0001179110-14-017420
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-02 17:42:15
- Reporting Period:
- 2014-12-01
- Filing Date:
- 2014-12-02
- Accepted Time:
- 2014-12-02 17:42:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1280600 | Acceleron Pharma Inc | XLRN | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1586835 | Ravindra Kumar | 128 Sidney Street Cambridge MA 02139 | Vp & Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-12-01 | 4,000 | $5.88 | 31,890 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-12-01 | 1,900 | $34.87 | 29,990 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-12-01 | 1,000 | $36.10 | 28,990 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-12-01 | 1,100 | $37.44 | 27,890 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option to Purchase Common Stock | Disposition | 2014-12-01 | 4,000 | $0.00 | 4,000 | $5.88 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 8,500 | 2018-12-17 | No | 4 | M | Direct |
Footnotes
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.49 to $35.11, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to $36.39, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.08 to $37.94, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant.
Billionaire Hedge Funds
